Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $168,188,006.77. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ UTHR opened at $518.53 on Wednesday. The firm’s 50-day moving average price is $531.75 and its 200-day moving average price is $538.30. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The firm has a market capitalization of $22.24 billion, a P/E ratio of 18.55, a P/E/G ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.41 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its holdings in shares of United Therapeutics by 55,526.2% in the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock valued at $18,036,953,000 after purchasing an additional 33,229,108 shares in the last quarter. BlackRock Inc. bought a new stake in United Therapeutics during the second quarter worth $2,868,735,000. Avoro Capital Advisors LLC grew its holdings in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Wellington Management Group LLP raised its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.